Evommune Announces Phase 2b Trial Failure for Lead Drug Candidate, EVO756
Evommune's stock dropped by approximately 38% after its lead drug candidate, EVO756, failed to meet the primary endpoint in a Phase 2b trial for chronic spontaneous urticaria. This failure significantly impacted shareholder value and removed Evommune’s nearest potential regulatory catalyst.
Tickers: $EVMN
Topics: biotech pharma_pipeline stock_drop